title: Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
abstract: Erythema nodosum (EN) is a panniculitis frequently encountered secondary to medical therapy. We present a case of a 66-year-old gentleman with JAK2-positive myelofibrosis who developed transient EN-like lesions on his trunk and upper and lower extremities approximately three weeks after starting lenalidomide therapy. The subcutaneous nodules improved with intralesional triamcinolone and topical clobetasol without discontinuation of lenalidomide.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(8):1024-1025.
authors.forename: Tatyana A
authors.initials: TA
authors.lastname: Petukhova
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Tartar
authors.forename: Karen
authors.initials: K
authors.lastname: Mayo
authors.forename: Maxwell A
authors.initials: MA
authors.lastname: Fung
authors.forename: Joseph
authors.initials: J
authors.lastname: Tuscano
authors.forename: Jared
authors.initials: J
authors.lastname: Jagdeo
mesh_terms: D000368:Aged; D004893:Erythema Nodosum / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D053614:Janus Kinase 2; D000077269:Lenalidomide; D008297:Male; D015434:Panniculitis / Q000139:chemically induced* / Q000175:diagnosis; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide